"009-016-00-2,trisodium hexafluoroaluminate [1],237-410-6 [1],13775-53-6 [1],  STOT RE 1    Acute Tox. 4    Aquatic Chronic 2  ,  H372    H332    H411  ,  GHS07    GHS08    GHS09    Dgr  ,  H372    H332    H411  ,,,,
trisodium hexafluoroaluminate (cryolite) [2],239-148-8 [2],15096-52-3 [2],
603-012-00-X,  2-ethoxyethanol;    ethylene glycol monoethyl ether  ,203-804-1,110-80-5,  Flam. Liq. 3    Repr. 1B    Acute Tox. 3    Acute Tox. 4  ,  H226    H360FD    H331    H302  ,  GHS02    GHS08    GHS06    Dgr  ,  H226    H360FD    H331    H302  ,,,,
603-025-00-0,tetrahydrofuran,203-726-8,109-99-9,  Flam. Liq. 2    Carc. 2    Eye Irrit. 2    STOT SE 3  ,  H225    H351    H319    H335  ,  GHS02    GHS07    GHS08    Dgr  ,  H225    H351    H319    H335  ,EUH019,  STOT SE 3;    H335: C ≥ 25 %    Eye Irrit.2;    H319: C ≥ 25 %  ,,
613-016-00-3,  fuberidazole (ISO);    2-(2-furyl)-1 H -benzimidazole  ,223-404-0,3878-19-1,  Carc. 2    Acute Tox. 4    STOT RE 2    Skin Sens. 1    Aquatic Acute 1    Aquatic Chronic 1  ,  H351    H302    H373 (heart)    H317    H400    H410  ,  GHS07    GHS08    GHS09    Wng  ,  H351    H302    H373 (heart)    H317    H410  ,,M = 1,,
617-001-00-2,di- tert -butyl peroxide,203-733-6,110-05-4,  Org. Perox. E    Flam. Liq. 2    Muta. 2  ,  H242    H225    H341  ,  GHS02    GHS08    Dgr  ,  H242    H225    H341"  ,,,,


‘015-199-00-X,tris[2-chloro-1-chloromethyl)ethyl] phosphate,237-159-2,13674-87-8,Carc. 2,H351,  GSH08    Wng  ,H351,,,,
015-200-00-3,indium phosphide,244-959-5,22398-80-7,  Carc. 1B    Repr. 2    STOT RE 1  ,  H350    H361f    H372 (lungs)  ,  GHS08    Dgr  ,  H350    H361f    H372 (lungs)  ,,  STOT RE 1;    H372: C ≥0,1 %    Carc 1B;    H350: C ≥0,01 %    STOT RE 2;    H373: 0,01 % ≤ C < 0,1 %  ,,
015-201-00-9,trixylyl phosphate,246-677-8,25155-23-1,Repr. 1B,H360F,  GHS08    Dgr  ,H360F,,,,
015-202-00-4,tris(nonylphenyl) phosphite,247-759-6,26523-78-4,  Skin Sens. 1    Aquatic Acute 1    Aquatic Chronic 1  ,  H317    H400    H410  ,  GHS07    GHS09    Wng  ,  H317    H410  ,,,,
015-203-00-X,diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide,278-355-8,75980-60-8,Repr. 2,H361f (causing atrophy of the testes),  GHS08    Wng  ,H361f (causing atrophy of the testes),,,,
602-109-00-4,Hexabromocyclododecane [1],247-148-4 [1],25637-99-4[1],  Repr. 2    Lact.  ,  H361    H362  ,  GHS08    Wng  ,  H361    H362  ,,,,
1,2,5,6,9,10-hexabromocyclododecane [2],221-695-9[2],3194-55-6[2],
606-143-00-0,abamectin (combination of avermectin B1a and avermectin B1b) (ISO) [1],_ [1],71751-41-2 [1],  Repr. 2    Acute Tox. 2    Acute Tox. 1    STOT RE 1    Aquatic Acute 1    Aquatic Chronic 1  ,  H361d    H300    H330    H372 (nervous system)    H400    H410  ,  GHS06    GHS08    GHS09    Dgr  ,  H361d    H300    H330    H372 (nervous system)    H410  ,,  STOT RE 1;    H372: C ≥ 5 %    STOT RE 2;    H373: 0,5 % ≤C<5 %    M = 10 000  ,,
avermectin B1a (purity ≥80 %); [2],265-610-3 [2],65195-55-3 [2],
606-144-00-6,  acequinocyl (ISO);    3-dodecyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl acetate  ,—,57960-19-7,  Skin Sens. 1    STOT SE 1    STOT RE 2    Aquatic Acute 1    Aquatic Chronic 1  ,  H317    H370 (lung)    (inhalation)    H373 (blood system)    H400    H410  ,  GHS07    GHS08    GHS09    Dgr  ,  H317    H370 (lung)    (inhalation)    H373 (blood system)    H410  ,,M = 1 000,,
607-698-00-1,4- tert -butylbenzoic acid,202-696-3,98-73-7,  Repr. 1B    STOT RE 1    Acute Tox. 4  ,  H360F    H372    H302  ,  GHS07    GHS08    Dgr  ,  H360F    H372    H302  ,,,,
612-281-00-2,  leucomalachite green;    N,N,N',N'-tetramethyl-4,4'-benzylidenedianiline  ,204-961-9,129-73-7,  Carc. 2    Muta. 2  ,  H351    H341  ,  GHS08    Wng  ,  H351    H341  ,,,,
616-205-00-9,  Metazachlor (ISO);    2-chloro-N-(2,6-dimethylphenyl)-N-(1H-pyrazol-1-ylmethyl)acetamide  ,266-583-0,67129-08-2,  Skin Sens. 1B    Carc. 2    Aquatic Acute 1    Aquatic Chronic 1  ,  H317    H351    H400    H410  ,  GHS07    GHS08    GHS09    Wng  ,  H317    H351    H410  ,,  M = 100    M = 100’  ,,

"009-016-00-2,trisodium hexafluoroaluminate [1],237-410-6 [1],13775-53-6 [1],  Xn; R20    T; R48/23/25    N; R51-53  ,  T; N    R: 20-48/23/25-51/53    S: (1/2-)22-37-45-61  ,,,
trisodium hexafluoroaluminate (cryolite) [2],239-148-8 [2],15096-52-3 [2],
603-012-00-X,  2-ethoxyethanol;    ethylene glycol monoethyl ether  ,203-804-1,110-80-5,  R10    Repr. Cat. 2; R60-61    Xn; R20/22  ,  T    R: 60-61-10-20/22    S: 53-45  ,,E,
603-025-00-0,tetrahydrofuran,203-726-8,109-99-9,  F; R11-19    Carc. Cat. 3; R40    Xi; R36/37  ,  F; Xn    R: 11-19-40-36/37    S: (2-)(13-)16-29-33-36-37(-46)  ,Xi; R36/37: C ≥ 25 %,,
613-016-00-3,  fuberidazole (ISO);    2-(2-furyl)-1 H -benzimidazole  ,223-404-0,3878-19-1,  Carc. Cat. 3; R40    Xn; R48/22    Xn; R22    Xi; R43    N; R50-53  ,  Xn; N    R: 40-48/22-22-43-50/53    S: (2)-22-36/37-60-61  ,  N; R50-53: C ≥ 25 %    N; R51-53: 2,5 % ≤ C < 25 %    R52-53: 0,25 % ≤ C < 2,5 %  ,,
617-001-00-2,di- tert -butyl peroxide,203-733-6,110-05-4,  O; R7    F; R11    Muta. Cat. 3, R68  ,  O; F; Xn    R: 7-11-68    S: (2-)3/7-14-16-23-36/37/39"  ,,,

‘015-199-00-X,tris[2-chloro-1-chloromethyl)ethyl] phosphate,237-159-2,13674-87-8,Carc. Cat. 3; R40,  Xn    R: 40    S: (2-)36/37  ,,,
015-200-00-3,indium phosphide,244-959-5,22398-80-7,  Carc. Cat. 2; R45    Repr. Cat. 3; R62    T; R48/23  ,  T    R: 45–48/23–62    S: 45- 53  ,  T; R48/23: C ≥0,1%    Carc Cat 2; R45: C ≥0,01%    Xn; R48/20: 0,01%≤ C < 0,1%  ,E,
015-201-00-9,trixylyl phosphate,246-677-8,25155-23-1,Repr. Cat. 2; R60,  T    R: 60    S: 53-45  ,,,
015-202-00-4,tris(nonylphenyl) phosphite,247-759-6,26523-78-4,  Xi; R43    N; R50-53  ,  Xi; N    R: 43-50/53    S: 24-37-60-61  ,,,
015-203-00-X,diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide,278-355-8,75980-60-8,Repr. Cat. 3; R62,  Xn    R: 62    S: (2)-22-36/37.  ,,,
602-109-00-4,Hexabromocyclododecane [1],247-148-4 [1],25637-99-4[1],Repr. Cat. 3; R63 R64,  Xn    R: 63-64    S: 36/37-53  ,,,
1,2,5,6,9,10-hexabromocyclododecane [2],221-695-9[2],3194-55-6[2],
606-143-00-0,abamectin (combination of avermectin B1a and avermectin B1b) (ISO) [1],_ [1],71751-41-2 [1],  Repr. Cat. 3; R63    T+; R26/28    T; R48/23/25    N; R50-53  ,  T+; N    R: 63-26/28-48/23/25-50/53    S: 28-36/37-45-60-61  ,  T; R48/23: C ≥ 5%    Xn; R48/20: 0,5% ≤ C <5%    N; R50-53: C ≥ 0,0025%    N; R51-53: 0,00025% ≤ C <0,0025%    R52-53: 0,000025% ≤ C<0,00025%  ,,
avermectin B1a (purity ≥80%); [2],265-610-3 [2],65195-55-3 [2],
606-144-00-6,  acequinocyl (ISO);    3-dodecyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl acetate  ,—,57960-19-7,  T; R39/23    Xi; R43    N; R50-53  ,  T; N    R: 39/23-43-50/53,    S: (2-)24-37-38-60-61  ,  N; R50-53: C ≥ 0,025%    N; R51-53: 0,0025% ≤ C < 0,025%    R52-53: 0,00025% ≤ C < 0,0025%  ,,
607-698-00-1,4- tert -butylbenzoic acid,202-696-3,98-73-7,  Repr. Cat. 2; R60    T; R48/23/24/25    Xn; R22  ,  T    R: 60-22-48/23/24/25    S: 53-45  ,,E,
612-281-00-2,  leucomalachite green    N,N,N',N'-tetramethyl-4,4'-benzylidenedianiline  ,204-961-9,129-73-7,  Carc. Cat. 3; R40    Muta. Cat. 3; R68  ,  Xn    R: 40-68    S: (2-)36/37  ,,,
616-205-00-9,  Metazachlor (ISO);    2-chloro-N-(2,6-dimethylphenyl)-N-(1H-pyrazol-1-ylmethyl)acetamide  ,266-583-0,67129-08-2,  R43    Carc. Cat. 3; R40    N; R50-53  ,  Xn; N    R: 40-43-50/53    S: (2-)36-37-60-61  ,  N; R50-53: C ≥ 0,25%    N; R51-53: 0,025% ≤ C < 0,25%    R52-53: 0,0025% ≤ C < 0,025%’  ,,